Market access update
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
|Written by Fishawack Health|
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals?
In this article, Fishawack Health reveals how life science companies can cut through the noise to drive uptake of innovative therapies, including novel TYK2 inhibitors.
Download the full article to:
- explore the treatment landscape
- learn about the barriers keeping healthcare professionals from prescribing treatments beyond topicals
- find out about strategies for driving uptake of novel psoriasis therapies.
PRMA Consulting is part of Fishawack Health, an independent global healthcare communications group.
Vaccine reimbursement: helping you prepare for success